Abstract: A method for obtaining at least one binding agent which binds a pharmaceutically active form of the compound with a higher specificity than a pharmaceutically inactive form of the compound is described by using special derivatives of said parent compound. The invention also pertains to the respectively created binding agents and derivatives. Furthermore, drug monitoring assays using said binding agents for monitoring pharmaceutically active forms of said parent compound are provided.
Type:
Grant
Filed:
November 7, 2011
Date of Patent:
December 11, 2012
Assignee:
Novartis AG
Inventors:
Patrick Albientz, Jean-Michel Grenet, Rainer Hillenbrand, Francois Legay, Peter Marbach, Severine Marrony, Judith Schaefer
Abstract: A stable solid hydrate of a muscarinic receptor antagonist is useful in the treatment of irritable bowel syndrome, diverticular disease, oesophageal achalasia, chronic obstructive airways disease, over active bladder (including symptoms of incontinence, urge and frequency), urinary incontinence, neurogenic urinary urgency or pollakiuria, treatment of bladder functional disorder, urinary leakage, painful or difficult urination caused by neurogenic bladder, spastic or hypertonic bladder, dysfunctional bladder syndrome, gastrointestinal disorders including gastrointestinal hyperactivity, and relaxing effect on intestinal smooth muscle cells.
Type:
Grant
Filed:
March 17, 2008
Date of Patent:
April 13, 2010
Assignee:
Novartis International Pharmaceutical Ltd.
Inventors:
Peter J Dunn, John G Matthews, Trevor J Newbury, Garry O'Connor